Tradename:

Marevan

Marevan

Composition:

Each tablet contains:

warfarin sodium 5 mg

Auxiliary components:

calcium hydrogen phosphate dihydrate, copovidone, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose.

Properties:

Indirect anticoagulant. Suppresses the synthesis of vitamin K-dependent blood coagulation factors (Il, Vll, IX and X) and proteins C and S in the liver in the liver.

The optimal anticoagulant effect is observed 3-5 days from the start of use and stops 3-5 days after the last dose.

Indications:

Treatment and prevention of thrombosis and vascular thromboembolism:

• acute venous thrombosis and pulmonary embolism;
• postoperative thrombosis;

-repeated myocardial infarction;

• as an additional drug in the surgical or thrombolvtic treatment of thrombosis, as well as in electrical cardioversion of atrial fibrillation;

-recurrent venous thrombosis;

• repeated pulmonary embolism;

-prosthetics of the valves of the heart and blood vessels (a combination with acetylsalicylic acid (ASA) is possible;

-thrombosis of peripheral, coronary and cerebral arteries;

• secondary prevention of thrombosis and thromboembolism after myocardial infarction and atrial fibrillation.

Method of administration and dosage:

The recommended daily dose is from 3 to 10 mg per day, depending on the indication. Take at the same time.

In the case of acute thrombosis, treatment is carried out in combination with heparin unti the effect of oral anticoagulant therapy is fu manifested (not earlier than 3-5 days of treatment).

When prosthetics of heart valves, acute venous thrombosis of veins or thromboembolism (at the initial stages), thrombosis of the left ventricle and for the prevention of myocardial ischemia, one should strive for an effective effect, which is observed with an INR of 2.8-4.0.

Contraindications:

• acute bleeding;

-severe liver disease;

-severe kidney disease;

• renal failure;
• severe arterial hypertension;

-Acute disseminated intravascular coagulation syndrome;

-deficiency of proteins C and S;

• hemorrhagic diathesis;

-thrombocytopenia;

• peptic ulcer of the stomach and duodenum in the acute phase;
• hemorrhage in the brain;

-alcoholism;

-pregnancy;

-increased sensitivity to drug components.

Precautions:

Before starting therapy, the INR indicator is determined (corresponding to the prothrombin time, taking into account the thromboplastin sensitivity coefficient). In the future, regular (every 2-4-8 weeks) laboratory control is carried out.

During the period of treatment, it is necess to refrain from using ethanol (the risk of developing hypoprothrombinemia and bleeding).

Side effects:

From the hematopoietic system: often bleeding.

From the digestive system: rarely – diarrhea, increased activity of hepatic transaminases.

Skin and subcutaneous tissue disorders: rarely – eczema, skin necrosis, vasculitis, hair loss.

Storage method:

At a temperature not higher than 30 degrees. In a dry place.

Packaging:

The cardboard box holds a can of 102 tablets.